Correction to: IGF-1C domain-modified hydrogel enhanced the efficacy of stem cells in the treatment of AMI.

An amendment to this paper has been published and can be accessed via the original article.

IGF-1C domain-modified hydrogel enhanced the efficacy of stem cells in the treatment of AMI.

Background: Due to the low survival rate of cell transplantation, stem cell has not been widely used in clinical treatment of acute myocardial infarction (AMI). In this study, we immobilized the C domain peptide of insulin-like growth factor-1 on chitosan (CS-IGF-1C) to obtain bioactive hydrogel. The purpose was to investigate whether CS-IGF-1C hydrogel incorporated with human placenta-derived mesenchymal stem cells (hP-MSCs) can boost the survival of hP-MSCs and enhance their therapeutic effects.